#opportunistic inf in #autoimmune dz 🎤 @khyrich 👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸) 👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6 👉 🙅‍♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️ 🔗#eular 2022 guide: https://t.co/PIpGpTrH28 #eular2024 #rheumx @RheumNow https://t.co/kouXvradiC

• https://ard.bmj.com/content/annrheumdis/82/6/742.full.pdf
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1

Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A

• https://twitter.com/i/web/status/1801590870908518546
• https://twitter.com/synovialjoints/status/1801590870908518546/photo/1

What is better in #PsA #psoriatic #arthritis #TNFi or #apremilast #PDE4i #COREVITAS database study in #PsA YOU can guess the answer! 1st line advanced RxTNFi lasts longer - retention Vs PDE4i #EULAR2024 @RheumNow @eular_org POS0990 https://t.co/VmYG6Rj87c

• https://twitter.com/Janetbirdope/status/1801585969130356929/photo/1

Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3

• https://twitter.com/i/web/status/1801585922292519240
• https://twitter.com/synovialjoints/status/1801585922292519240/photo/1
• https://twitter.com/synovialjoints/status/1801585922292519240/photo/1

The age old question in #inflammatory #arthritis Should you cycle within TNFi class or move on to another MOA in #PsA #psoriatic #arthritis Better retention to go to a IL17i vs another TNFi in observational study comparing the 2 POS0266 #EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9

• https://twitter.com/Janetbirdope/status/1801582359914897665/photo/1
• https://twitter.com/Janetbirdope/status/1801582359914897665/photo/1

Can you predict which pts with #PsA #psoriatic #arthritis Will respond to #TNFi #Rx? Well, 🤔 maybe Needs validation and an easy reliable inexpensive biomarker! #EULAR2024 @RheumNow @eular_org POS0992 https://t.co/Ce92561AMO

• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1
• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1

Swedish/Danish cohort study in PsA 17000+ bionaïve 8000+ TNFi & 2000+ other MoA Overall non melanoma skin cancer rate 651 (505 BCC & 87 SCC) TNFi treated pts: HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50) HR 1.19 NMSC vs. other MoA (ns) #EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6

• https://twitter.com/AurelieRheumo/status/1801230838136213897/photo/1

OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs >1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs @RheumNow #EULAR2024